Oral versus vaginal Lactobacillus supplementation for endometrial dysbiosis: A paired pre and post-endometrial microbiome study.

OA: gold CC-BY-4.0
📄 Open PDF View on PubMed View at publisher

Abstract

Infertility is a global health challenge, and impaired endometrial receptivity remains an important contributor to treatment failure. Endometrial dysbiosis, characterized by a low proportion of Lactobacillus in the endometrial microbiota, has been proposed as a potentially modifiable factor that may affect endometrial receptivity and fertility, and treatment with Lactobacillus-containing probiotics is emerging as a promising therapeutic approach. However, the optimal route of Lactobacillus supplementation remains unclear. We compared oral versus vaginal supplementation using the same Lactobacillus-containing formulation as an adjunct to standardized doxycycline/metronidazole therapy and continued oral lactoferrin in patients with baseline endometrial Lactobacillus <10%, based on paired microbiome profiling of endometrial samples (aspirated intrauterine fluid and endometrial tissue). In this single-center retrospective cohort study, thirty-two patients underwent paired endometrial microbiome testing before and after 30 days of supplementation (oral, n = 18; vaginal, n = 14). In the vaginal group, the median endometrial Lactobacillus proportion increased from 0.05% [0.00-0.20] to 99.15% [70.45-100.00] (p = 0.001), whereas in the oral group it increased from 0.00% [0.00-0.18] to 0.30% [0.03-66.33] (p = 0.005). The median change was greater with vaginal versus oral supplementation (+98.90% [70.45-99.80] vs + 0.25% [0.03-66.33], p < 0.001). Post-treatment Lactobacillus ≥80%, used as an exploratory marker of marked microbiota improvement, was observed in 9/14 patients (64%) in the vaginal group and 3/18 (17%) in the oral group (p = 0.010). Exploratory reproductive outcomes were limited by the small sample size and did not define a reliable clinical threshold. These findings suggest that, within this combined treatment regimen, vaginal Lactobacillus supplementation may provide a greater route-associated additional improvement in endometrial microbiota profiles than oral administration.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

SciLite annotations

organisms 69
paralactobacillus paralactobacillus microbiota paralactobacillus paralactobacillus paralactobacillus paralactobacillus microbiota paralactobacillus microbiota paralactobacillus microbiota paralactobacillus microbiota paralactobacillus microbiota paralactobacillus paralactobacillus microbiota noordeloos 2009062 paralactobacillus paralactobacillus human paralactobacillus paralactobacillus paralactobacillus vkm:b:574 bacteria stick insect paralactobacillus paralactobacillus paralactobacillus microbiota paralactobacillus microbiota microbiota microbiota paralactobacillus paralactobacillus microbiota paralactobacillus paralactobacillus paralactobacillus paralactobacillus paralactobacillus paralactobacillus microbiota paralactobacillus paralactobacillus microbiota paralactobacillus vkm b-1660 vkm:b:574 paralactobacillus vpi 3199 lmg:18914 paralactobacillus paralactobacillus paralactobacillus paralactobacillus paralactobacillus +9 more
chemicals 20
doxycycline metronidazole doxycycline metronidazole doxycycline metronidazole hydroxypropyl methylcellulose carrageenan potassium chloride hexamethyldisiloxane fatty acid ester starch calcium stearate silicon dioxide water doxycycline metronidazole doxycycline doxycycline metronidazole

Source provenance

europepmc
last seen: 2026-11-01T09:25:17.647243+00:00
scilite
last seen: 2026-11-01T10:01:09.713090+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC